PropThink: Illumina Third Quarter Results Highlight Solid Growth Prospects
(Thomson Reuters ONE) -
By Ivan Deryugin
One of the most pressing issues that the market faces today is what kind of
impact the fiscal cliff will have on companies in the healthcare sector; the
life science sector has been particularly impacted. These concerns have put
pressure on the shares of many of those companies, but investors have been
painting the sector with too broad a brush. One company in particular is posting
solid growth and has proven itself to be resilient against weakness in all three
geographic areas of concern for the markets: the United States, Europe, and
China.
San Diego-based Illumina, Inc. (NASDAQ:ILMN) is one of the world's leading
genetic sequencing and testing companies, with just over $1 billion in revenues
over the past 12 months. And although Illumina's stock has dramatically
outperformed the S&P 500 year to date, it is due in large part to the impact of
Roche's hostile takeover attempt early this year. Illumina's shares remain well
below their 2011 highs, even though the company's fundamentals have never been
better. Illumina's Q3 2012 results are those of a company whose best days are
ahead of it, and whose value the market is discounting. Unless otherwise noted,
financial facts and management commentary will be sourced from either Illumina's
Q3 2012 earnings call or its Q3 2012 earnings release.
Overview
Illumina posted its Q3 2012 results after the markets closed on October 23. Its
revenues of $285.874 million matched analyst estimates, and pro forma EPS of
$0.41 beat estimates by 2 cents. Revenues grew by 21.39% year over year, and pro
forma EPS grew by 86.37%. On a GAAP basis, Illumina's EPS grew by just 46.67%.
Illumina's 2012 income statement has been filled with several extraordinary
charges, which distort its GAAP earnings. Illumina's move to new headquarters
has resulted in the payment of double rent, as well as cease-use losses, and
lease exit liabilities. In Q3 alone, the company had charges of 15 cents per
share associated with relocating its headquarters. The company has said that
these relocation charges are not expected to be material going forward. The
second major driver of the discrepancy between GAAP and non-GAAP earnings are
costs associated with fighting off Roche's hostile takeover. This latest quarter
included 3 cents of charges associated with the Swiss company's tender offer,
which are set to decline over the next several quarters.
Margins: Leading the Life Science Industry
As the table above shows, Illumina is the clear margin leader in the life
science industry, at both the gross and operating level. Unlike its peers,
Illumina has just two focus product areas: genetic sequencing and testing.
Everything that the company does revolves around those areas, and Illumina's
decision to do so has paid off. Sequencing and genetics are the fastest growing
areas of the diagnostics market. They grew at a 17% clip in 2011, and they are
projected to be worth $25 billion within a decade, up from the $5.6 billion that
they are worth today.
In Q3, Illumina's gross margin came in at 70.5%, up from 68.9% in the third
quarter of 2011. Though it declined sequentially (from 70.9%), it is because
Illumina sold more sequencing systems in the quarter relative to consumables.
Illumina's Q3 operating margin came in at 35.1%, up from 29.3% a year ago, due
to solid revenue growth and tight cost controls. SG&A expenses totaled 19.5% of
revenue in Q3 compared to 22.2% a year ago. This allowed operating margins to
expand, even though Illumina's R&D spending rose by 12.49% as the company
invested aggressively in its new sequencing systems. Illumina's focus on a fast
growing market, and its leadership position within that market, give it
industry-leading margins, and they are expanding.
Competition: Beating its San Diego Neighbor
In sequencing, Illumina's fiercest competitor is its neighbor Life Technologies
(NASDAQ:LIFE), which is based in Carlsbad, just north of San Diego. Life, via
its Ion Proton and Ion Torrent systems, has been making an aggressive push to
compete with Illumina. And given that Life is almost 4 times as large as
Illumina (based on sales), many investors assume that Life will surpass Illumina
in the sequencing market. The results, however, tell a different story. Analysts
pressed Illumina on its Q3 call about the effects of competition, and CEO Jay
Flatley said:
Let's take that [the high end sequencing market] first. Things are going really,
really well with 2500 and the 2000 sales as we indicated in the script. We had
very strong performance that exceeded our expectations in the high end of the
market. And we essentially have no competition in that part of the market. In
the desktop, I'd say, if anything, our competitive position has continued to
improve there. The new launch of a competitive instrument into the field is,
from any customer we've talked, to not performing to specifications. And so
we're not seeing our customers get distracted by that system. We're seeing
already some pretty heavy discount offers of that system into the marketplace.
And our MiSeq product continues to perform really, really well. And we're
upgrading the output in the system, and the customers are continuing to get
great data with BaseSpace enabled for storage and for data sharing. So all of
the attributes, ease of use of our system continue to make it very, very
competitive. And certainly, the output ranges that customers are achieving with
this exceed the output ranges of any competitive systems in the desktop market.
Life Technologies is already discounting its sequencing systems to generate
consumer demand, even though its systems are already priced lower than
Illumina's. Customers understand that Illumina's systems have better quality and
performance, and they are willing to pay a premium to take advantage of those
factors. MiSeq launched 12 months later than Life's desktop sequencing
platforms, and despite a higher price, it already has 50% unit share (per CEO
Jay Flatley), and a far higher revenue share. If Illumina can continue to
execute as it has in Q3, those market share figures should continue to increase.
Geographic Results: Macroeconomic Weakness? Where?
Investors in the life sciences industry have been forced to deal with the twin
worries of NIH funding cuts and macroeconomic stress in 3 key markets: Europe,
China, and the United States. Illumina's results, however, seem to show none of
these stress points. In Q3, the company posted solid product shipment growth
across all key geographies. Product shipments in the United States grew 19% in
the quarter, accelerating from the 18% growth rate posted in Q2 2012. Shipments
to Europe also grew 19% during the quarter, and shipments to China rose by 79%,
up from a 50% growth rate posted during Q2 2012 (overall Asian shipments were up
21%). While Illumina did not disclose its Q2 European product shipment growth,
it did note that its European business remains stable, and that shipments to
Spain and Italy grew sequentially during the quarter. How many companies can
claim not only sequential growth in Spain and Italy, but also 19% growth in
Europe as a whole? Not many. Illumina is riding a secular growth story, one that
has proven to be resilient to macroeconomic stress.
In China, Illumina, like most life science companies, is benefitting from the
government's push to expand healthcare access to the western part of the
country. This is an integral part of the country's current 5-year plan, and it
will probably feature prominently in future 5-year plans as well. Expanded
access to social services and general job security are part of the implicit
social contract that exists between the Communist government and the people of
China. The life science industry as a whole, in fact, confirms that China is a
source of strength. PerkinElmer (NYSE:PKI), for example, is very upbeat about
growth in China, as its leadership in the neo-natal testing market makes it the
medical sector's choice for expanding screening of pregnant women and newborns.
Waters (NYSE:WAT) stated on its own Q3 2012 conference call, "General concerns
that we have recently heard regarding a slowing of economic growth in China are
not apparent in our third quarter results or in the outlook that we have in the
fourth quarter." And Thermo Fisher (NYSE:TMO) posted 20% growth in China in Q3.
Companies that operate in both life sciences and industrials, such as Danaher
(NYSE:DHR), or Sigma-Aldrich (NASDAQ:SIAL) do note weakness in China's
industrial sector, as does PerkinElmer (where industrials make up 7% of overall
sales). But for "pure" life sciences companies such as Illumina, macroeconomic
stress in China is nowhere to be found. In the United States, concerns about the
fiscal cliff, and specifically the 8.2% cut to NIH funding that is part of the
automatic spending cuts slated to go into effect in 2013, have pressured shares
of life science companies for some time. Here, companies in the sector have
reported different things, and it is due to differing product lines and areas of
strength. Danaher, for example, has said that customers are slowing down ahead
of the NIH's cuts. Water has also said that demand in the United States was more
constrained than the company anticipated during the latest quarter.
Illumina, however, appears immune to these macroeconomic pressures. To continue
reading, click here.
See this report in full at PropThink.com.
About PropThink
PropThink is an intelligence service that delivers long and short trading ideas
to investors in the healthcare and life sciences sectors. Our focus is on
identifying and analyzing technically-complicated companies and equities that
are grossly over or under-valued. We offer daily market coverage, weekly feature
stories, and a newsletter to investors who subscribe on PropThink.com. To learn
more, follow us on Twitter or visit us at http://www.propthink.com.
Disclaimer:
You should assume that as of the publication date of any report or letter,
PropThink, LLC and persons or entities with whom it has relation ships
(collectively referred to as "PropThink") has a position in all stocks (and/or
options of the stock) covered herein that is consistent with the position set
forth in our research report. Following publication of any report or
letter, PropThink intends to continue transacting in the securities covered
herein, and we may be long, short, or neutral at any time hereafter regardless
of our initial recommendation. To the best of our knowledge and belief, all
information contained herein is accurate and reliable, and has been obtained
from public sources we believe to be accurate and reliable, and not from company
insiders or persons who have a relationship with company insiders. PropThink was
not compensated to publish this article. Our full disclaimer is available
at http://www.propthink.com/disclaimer.
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: PropThink via Thomson Reuters ONE
[HUG#1654423]
Unternehmensinformation / Kurzprofil:
Datum: 01.11.2012 - 14:00 Uhr
Sprache: Deutsch
News-ID 198689
Anzahl Zeichen: 12509
contact information:
Town:
New York
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 174 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"PropThink: Illumina Third Quarter Results Highlight Solid Growth Prospects"
steht unter der journalistisch-redaktionellen Verantwortung von
PropThink (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
